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Comparison of Antibodies That Mediate HIV Type 1
gp120 Antibody-Dependent Cell-Mediated Cytotoxicity
in Asymptomatic HIV Type 1-Positive Men and Women
Mariana M. Mata,1 Joyce R. Iwema,1 Shanna Dell,2 Leslie Neems,3 Beth D. Jamieson,4 John Phair,5
Mardge H. Cohen,6 Kathryn Anastos,7 and Linda L. Baum1

Abstract

Recent studies suggest that HIV-specific antibody-dependent cell-mediated cytotoxicity (ADCC) antibodies
contribute to protective immunity against HIV. An important characteristic of future HIV vaccines will, therefore, be the ability to stimulate production of these antibodies in both men and women. Early studies suggest
that men may have a better ADCC antibody response against HIV than women. Our objective was to determine
whether men and women differ with respect to their ADCC response to HIV-1 gp120. HIV-positive, asymptomatic untreated men and women were matched for race, age, CD4 + T cell number, HIV-1 viral load, and
treatment and HIV-1 gp120 ADCC antibody titers were compared. A standard 51Cr-release assay was used to
determine HIV-1 gp120 ADCC antibody titers in HIV-1-seropositive individuals from the Multicenter AIDS
Cohort Study (MACS; n = 32) and the Women’s Interagency HIV Study (WIHS; n = 32). Both sexes had high
ADCC titers against HIV-1 gp120: 34.4% (n = 11) and 40.6% (n = 13) of men and women, respectively, had titers of
10,000; 62.5% (n = 20) and 56.3% (n = 18) had titers of 100,000. Groups did not differ in percent specific release (%
SR), lytic units (LU), correlations of titer to viral load, or titer to CD4 + T cells in men or women. Both groups also
had similar cross-clade ADCC antibody responses ( p > 0.5 for % SR and LU). Comparable groups of asymptomatic HIV-1-infected men and women had comparable HIV-1 gp120 ADCC antibodies. Both sexes had significant cross-clade reactivity. Differences between men and women may become evident as disease progresses;
this should be evaluated at later stages of HIV-1 infection.

In ADCC, Fc receptor-bearing cells, such as natural killer
(NK) cells and monocytes, together with virus-specific antibody, bind to HIV envelope on infected cells and kill them.
This reduces the number of cells producing virus, lowers viral
load, and slows pathogenesis.
It is not surprising that ADCC antibodies would be considered an important component of a vaccine or a therapeutic tool since monoclonal antibodies that have functional
ADCC activity are used therapeutically to treat cancer.4
There have been efforts to enhance ADCC-mediated killing
by removing fucose from ADCC antibodies5 and to characterize the HIV epitopes that are recognized by these

Introduction

R

esults from RV144, a human vaccine trial for HIV
in Thailand, indicate that approximately 30% of subjects may have been protected. This is perplexing because the
two major immune effector mechanisms thought to be responsible for protection, cytotoxic T lymphocytes (CTL) and
neutralizing antibodies, were not present in immunized individuals.1 Further analysis revealed an inverse correlation
between HIV-env-specific antibody-dependent cell-mediated
cytotoxicity (ADCC) antibodies and risk of infection.2,3 This
has spurred a renewed interest in ADCC.
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antibodies.6 Strong support for ADCC as an important
component of vaccines against retroviruses comes from a
study by Alpert et al. in which rhesus macaques were vaccinated with a live attenuated vaccine and challenged with
neutralization-resistant simian immunodeficiency virus
(SIV). Animals with envelope-specific ADCC antibodies
were protected, suggesting that ADCC antibodies were essential for protection mediated by this retrovirus vaccine.7
Other recent studies supporting a role for ADCC in host
defense against HIV include evidence of its ability to prevent
HIV transmission through breastfeeding,8 confirmation that
ADCC killing correlates inversely with viral load,9 and the
suggestion that ADCC exerts immune pressure on HIV
replication.10–12 If ADCC antibodies are an important part of
the immune defense against HIV, it is important to determine whether HIV vaccines that are designed to stimulate an
ADCC response against HIV will work equally well in men
and in women.
The Multicenter AIDS Cohort Study (MACS) is an ongoing, NIH-sponsored, prospective study of HIV infection in
men who have sex with men (MSM). It was initiated in 1984.
The more than 7,000 participants in this study are homosexual and bisexual men who report participation in activities that put them at high risk of HIV infection; once enrolled,
they have a semiannual interview, physical and mental
evaluation, and HIV testing and treatment. They also provide clinical samples that have been used to establish a national repository that can be accessed by basic and clinical
investigators in order to study different aspects of HIV disease. MACS sites include Los Angeles, Chicago, Baltimore/
Washington, and Pittsburg.
The Women’s Interagency HIV Study (WIHS) is an ongoing, NIH-sponsored, prospective study of HIV infection in
women. It was established in 1993. Women who enroll in the
WIHS are interviewed and receive a physical examination
including a gynecologic examination and laboratory testing.
They also provide clinical samples that contribute to a valuable repository that can be used to study the HIV epidemic.
Until recently there were six WIHS sites: New York City/
Bronx, Brooklyn, Washington, D.C., Chicago, Northern California, and Southern California, with a Data Coordinating
Center in Baltimore. Four new sites have recently been established that represent areas of the South Eastern regions of
the United States where HIV infection rates in women are
high and increasing.
Our previous work demonstrates that in HIV-1-infected
individuals with a wide range of viral loads, ADCC antibody
titer correlates with the absolute CD4 + T cell number.13
Furthermore, we show that ADCC antibodies against HIV-1
are beneficial to the host and that high titers of antibodies
correlate not only with higher CD4 T cell numbers, but also
with a lower viral load.14 These were separate studies of
ADCC activity in 394 carefully chosen samples from 118
HIV-1-infected men from the Multicenter AIDS Cohort
Study (MACS)14 and 330 women from the Division of AIDS
Treatment and Research Initiative (DATRI 009).15 Even
though the purpose of the MACS study was to show a correlation with disease progression and the purpose of the
DATRI study was to report ADCC activity in the genital
fluids of HIV-infected women, one striking observation from
these studies was that men from the MACS had higher %
specific release (% SR), higher lytic unit (LU) values, and
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higher ADCC antibody titers than women from the DATRI
009 study. For example, men had LU values as high as 1,101
and a LU of 500–600 was frequent. The focus of the DATRI
study was genital ADCC, but paired serum ADCC activity
was evaluated for each woman. While greater than 90% of
women had serum ADCC activity, women more commonly
had LU values 10-fold lower than men. While each cohort
was composed of HIV-1-infected subjects from a single sex,
they had different demographic and clinical criteria for
enrollment.
The participants in the MACS were primarily homosexual
or bisexual white men whereas the participants in the DATRI
009 cohort were predominantly heterosexual AfricanAmerican women. The MACS samples were longitudinal
samples from carefully selected groups of rapid progressors,
moderate progressors, and long-term survivors while the
DATRI 009 samples were cross-sectional samples from
women at various stages of disease progression. The men had
not been treated at the time the samples were collected since
we utilized archived samples that had been stored prior to the
availability of antiretroviral medications. Samples from the
DATRI 009 study were actually collected a decade later than
the MACS samples and included participant women some of
whom had been treated with antiretroviral drugs because of
their more advanced HIV disease.
Since there were many possible explanations for the apparent sex difference in ADCC activity in previous studies, we
designed a more controlled study to compare ADCC antibodies in men and women. We obtained current matched
samples from the MACS and from one of the cohorts that had
contributed to the DATRI 009 sample set, the Women’s Interagency HIV Study (WIHS), in order to determine whether
the apparent differences between serum ADCC activity in
men and women were related to sex as opposed to other
factors such as race, age, stage of disease, viral load, or antiretroviral treatment. Serum samples in this study were all
from HIV-1-infected asymptomatic men and women who
were not on retroviral treatment. These samples were matched for age, race, and absolute numbers of CD4 + T cells and
assayed for ADCC antibody activity. This study was not designed to correlate ADCC activity with disease progression
since the study participants were relatively healthy and the
ranges of CD4 + T cells and viral loads were narrow.
In addition to determining if men and women had similar
ADCC antibody titers against HIV-gp120, we also wanted to
determine whether there were differences in cross-clade reactivity between HIV-1-infected men and women. Following
an initial assessment of sex differences in ADCC activity
against homologous clade B-derived HIV-1 gp120, which is
prevalent in North, Central, and South America and most of
Europe,16,17 we looked for differences in ADCC activity
against heterologous clade A/E-derived HIV-1 gp120, which
is prevalent in Thailand.18
Evidence from separate published studies that suggest that
sex differences in the ADCC antibody response to HIV, coupled with differences in HIV-1 disease progression in men and
women,19,20 lead to the concern that vaccines designed to
stimulate the production of ADCC antibodies might not work
equally well in men and women. In this study we directly
compared ADCC antibody activity against HIV in groups of
HIV-1-infected men and women who were carefully matched
with respect to age, race, and CD4 T cell number.
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Materials and Methods

Target cells

Study population

A natural killer (NK) cell-resistant CD4 + cell line,
CEM.NKR (NIH AIDS Research and Reference Reagent Program, Germantown, MD), was used as target cells in a standard 51chromium (51Cr)-release assay. When cells are labeled
in log phase, this cell line has less than 5% SR activity in the
absence of antibody (background NK cell activity) and more
than 90% of these cells bind and retain HIV-1 gp120 for the
duration of the assay.14 In chromium-release assays, 6 · 106
target cells in RPMI-1640 (Invitrogen Corp., Carlsbad, CA)
with 10% fetal bovine serum (FBS) (Atlanta Biologicals, Lawrenceville, GA) were incubated with 100 lCi of Na[51Cr]O7
(Perkin Elmer, Downers Grove, IL) for 1 h at 37C in a humidified 5% CO2 incubator. Following incubation, 1 · 106 cells
were washed and pulsed with 0.225 lg of recombinant HIV-1
MN gp120 (Immunodiagnostics, Inc., Woburn, MA) or
0.225 lg of recombinant HIV-1 CM gp120 (Protein Sciences
Corp., Meriden, CT) at room temperature for 1 h. The cells
were washed and 1 · 104 of target cells bearing rgp120 were
added to each microtiter well.

Serum samples were obtained from the MACS (n = 32)
and from the WIHS (n = 32); all subjects were asymptomatic HIV-1-seropositive individuals who reported no prior
antiretroviral therapy. The MACS is a prospective continuing study designed to evaluate the impact of HIV-1
infection in men; it has sites in Baltimore, Pittsburg, Chicago, and Los Angeles. The WIHS is a prospective cohort
study designed to evaluate the impact of HIV-1 infection
in women; it has sites in New York, Washington, D.C., San
Francisco, Southern California, and Chicago. Both studies
conducted interviews, physical examinations, and specimen sampling at enrollment with similar follow-up visits
every 6 months.19,20 The women in this study were taking
a variety of oral contraceptives. The MACS and WIHS
seropositive samples selected for this study were matched
for CD4 + T cell number, plasma viral load, age, and ethnicity (Table 1). Since individuals selected for this specific
study were not seroconverters, but were seroprevalent
when they entered these prospective studies, we do not
know whether the men and women we studied were infected for comparable lengths of time. All of the 64 individuals studied are most probably HIV-1 clade B since all
of the men and 29 of the women were from North
America. The remaining three women were from Granada,
Honduras, and Jamaica. Clade B is also the predominant
clade in these countries.21–23 In addition, five female and
five male HIV-1-seronegative serum samples were obtained from healthy donors who were not participants of
either the MACS or WIHS cohort.

Table 1. Characteristics of Study Participants

Male
Female
Age (years)
Mean
Median
Range
Log (viral load, copies/ml)
Mean
Median
Range
CD4 cell count (cells/ll)
Mean
Median
Range
Ethnicity [n, (%)]
White, Hispanic
Black, non-Hispanic
Hispanic
Other

MACS

WIHS

32
0

0
32

37.0 – 7.8a
36.3
22.0–52.2

39.7 – 9.3
38.1
22.4–57.3

3.77 – 0.91
3.87
1.86–5.32

3.32 – 0.88
3.54
1.90–5.38

551 – 108
529
400–756

583 – 125
545
401–797

4
21
5
2

4
21
5
2

(12.5)
(65.6)
(15.6)
(6.3)

(12.5)
(65.6)
(15.6)
(6.3)

a
Mean – standard deviation.
Study participants from the Multicenter AIDS Cohort Study
(MACS) and Women’s Interagency HIV Study (WIHS) (n = 32/32)
were systematically matched for age, HIV-1 viral load, CD4 cell
count, and ethnicity prior to evaluating sex differences in antibodydependent cell-mediated cytotoxicity (ADCC) against HIV-1 gp120.

Effector cells
Peripheral blood mononuclear cells (PBMC) were freshly
isolated from healthy HIV-1-seronegative donors by Ficoll gradient centrifugation using lymphocyte separation medium
(Mediatech Inc., Manassas, VA). The PBMC were rotated with
carbonyl iron (Sigma, St. Louis, MO) for 1 h followed by magnetic
separation to remove the monocytes and isolate the peripheral
blood leukocytes (PBL). The PBL were washed and resuspended
at a concentration of 8 · 106 cells/ml, 4 · 106 cells/ml, and 2 · 106
cells/ml in complete media to achieve effector to target (E:T) cell
ratios of 40:1, 20:1, and 10:1, respectively.
Antibody source
Sera from HIV-1-seropositive MACS (n = 32) and WIHS
(n = 32) participants were used as the source of antibodies. To
accurately compare HIV-1 gp120-specific ADCC titers in
males and females, 10-fold serum dilutions ranging from
1:100 to 1:100,000 were evaluated. Since the serum concentrations with maximum activity were determined in the initial
analysis, these peak dilutions were assayed to evaluate gp120
cross-clade reactivity. Pooled IgG from HIV-1-seropositive
individuals, HIVIg (North America Biologicals, Miami, FL),
was used as a positive control in all 51Cr-release assays at a
1:2,000 dilution, which was previously determined to be optimal. HIV-1-seronegative sera from healthy male and female
donors (m/f = 5/5) were obtained and diluted the same way as
the experimental samples for all assays.
Chromium release assay
A total of 1 · 104 target cells (in 100ll) were added to wells of
a 96 V-bottom plate (Corning, NY) and 50 ll of study serum
was added to give final dilutions of 1:100, 1:1,000, 1:10,000, and
1:100,000. After a 10-min incubation of target cells and serum,
50 ll of the effector cells was added to each well at the appropriate concentration to give the three E:T ratios. To determine
spontaneous and maximum release values, target cells were
incubated with either 100 ll of complete media or 100 ll of 0.1%
Triton X-100 (Sigma, St. Louis, MO). Plates were then incubated for 3.5 h in a humidified 37C/5% CO2 atmosphere.
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Cultures were assayed in quadruplicate. After incubation,
100 ll of the supernatant was harvested from each well and
c-irradiation was measured as counts per minute (cpm) using a
2470 Wizard Gamma Counter (Perkin Elmer, Torky, Finland).
cpm were converted to % SR according to the following formula: % SR = [(experimental CPM – spontaneous CPM)/
(maximum CPM – spontaneous CPM)] · 100. Percent SR from
three E:T values was used to determine lytic unit20 (LU20)
values. A LU20 is roughly based on the number of effector cells
required to lyse 20% of the target cells added to a well. This
number was calculated for each dilution using the exponential
fit method developed by Pross and Maroun.24
ADCC titer
We assessed the serum of 10 healthy HIV-1-seronegative
donors (m/f = 5/5) to establish a baseline ADCC response.
HIV-1 gp120-specific ADCC antibody titers were obtained
from % SR and LU20 values at each antibody dilution. Background NK activity (activity in the absence of antibody) for
the individual assay was subtracted to standardize results
prior to comparison of data. ADCC antibody titers were determined by taking the inverse of the highest antibody dilution at which HIV-1 gp120-specific ADCC activity was more
than three standard deviations greater than the mean activity
of the seronegative donors and greater than the no antibody
control. Percent SR, LU20, and ADCC titers were used since
not all of the antibody present in an individual’s serum is
capable of mediating functional ADCC activity.
Statistical analysis
Percent SR and LU20 values of all serum samples at each
antibody dilution were calculated. Means and medians – standard deviations or standard errors (SD, SE) of % SR
and LU20 values from each cohort were obtained. A positive
ADCC response was assigned to samples with an activity > 3
SD above the mean of our seronegative subjects. After determination of gp120-specific antibody titers, differences
between groups were assessed using a Student’s two-tailed
t-test and confirmed using Mann–Whitney. Only one individual from each cohort had no ADCC response. Their data
were included in the statistical analysis. When simultaneously
comparing between and within groups, two-way ANOVA
measures were used. Relationships between groups were assessed using the Pearson’s correlation. In all statistical analysis, results were considered significant when the p value was
< 0.05. In this study, all statistical analysis and graphing were
done using GraphPad Prism v.5 software (La Jolla, CA).
Results
ADCC antibody titers against HIV-1gp120 in infected
men and women
The demographic and clinical characteristics of matched
participants are described in Table 1. The mean absolute
CD4 + T cell counts of both men and women were greater than
500 cells/ll and the log of the viral load was < 4.0. Two-tailed
Student’s t-tests between men and women revealed no significant differences in serum ADCC activity when results
were calculated as % SR ( p = 0.97) or LU20 ( p = 0.87) (Fig. 1). In
fact, these results were remarkably similar, which makes it
likely that comparable results would be seen in a similar

FIG. 1. HIV-1-gp120 serum antibody-dependent cellmediated cytotoxicity (ADCC) antibodies in untreated
asymptomatic HIV-1-infected men and women. Fresh ADCC
effector cells from uninfected healthy donors were incubated
for 3.5 h with 51Cr-labeled HIV-1-gp120 bearing CEM.NKR
target cells in the presence of serum (10-fold serial dilutions)
from HIV-1-infected men (n = 32) from the Multicenter AIDS
Cohort Study (MACS), women (n = 32) from the Women’s
Interagency HIV Study (WIHS), and from uninfected donors
(n = 5 males/5 females) who were not participants from either the MACS or WIHS cohorts. Each effector:target cell
ratio (E:T) and serum dilution was assayed in quadruplicate.
(A) Mean ( – SE) % specific release (% SR) values for HIV-1 +
(closed symbols) and HIV-1 - (open symbols) women (circles) and men (triangles) are compared. (B) Mean % SR
values at each E:T were used to calculate lytic unit20 (LU20)
values. LU20 values of individuals from the WIHS (circles)
and the MACS (triangles) cohorts are compared.

comparison even if the sample size were considerably larger.
Furthermore, there were no variations between men and
women in % SR or LU20 values at any of the serum dilutions
evaluated ( p > 0.1 in all two-tailed Student’s t-tests and
Mann–Whitney tests). Both groups had high ADCC antibody
titers of 10,000 or 100,000 against HIV-1 gp120 when compared to seronegative controls, with the exception of two seropositive individuals (one from each cohort), who by
definition have antibodies to HIV, but had an HIV-1 gp120
ADCC antibody titer of 0, indicating that no functional ADCC
antibody activity was detected (Table 2).
Association of ADCC antibody titer with CD4 + T cell
number and HIV-1 viral load
For our study groups, we selected infected individuals who
were asymptomatic and not on drug treatment. This eliminated variables that could be responsible for differences in
ADCC activity between men and women, but it also limited
our ability to characterize differences early after infection or
later in disease progression because it provided a group of
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Table 2. Antibody-Dependent Cell-Mediated
Cytotoxicity Serum Antibody Titers of Men
and Women from the Multicenter AIDS
Cohort Study and Women’s Interagency HIV Study
Antibody titer
0
10,000
100,000

MACS

WIHS

1 (3.1)
8 (25.0)
23 (71.9)

1 (3.1)
9 (28.1)
22 (68.8)

Study participants from the Multicenter AIDS Cohort Study
(MACS) and Women’s Interagency HIV Study (WIHS) cohorts
(n = 32/32) were evaluated for antibody-dependent cell-mediated
cytotoxicity (ADCC) against HIV-1 gp120-coated CEM.NKR targets
in a standard 51Cr-release assay. ADCC antibody titers were
determined based on percent specific release values. The number
and percentage of observed ADCC antibody titers in men and
women are depicted. ADCC antibody titers of 100 and of 1,000 were
not observed among subjects from either cohort.

study participants who had a narrow range of CD4 + T cell
numbers and viral loads. As expected, Pearson’s correlations
between ADCC antibody titers and CD4 + T cell number were
not statistically significant when samples were matched for
age, race, and CD4 + T cell number in either sex-based group
[(r = 0.03, p = 0.87), (r = - 0.09, p = 0.61), men and women, respectively]. Nor did ADCC antibody titer show a relationship
to HIV-1 viral load in men or women, respectively [(r = - 0.21,
p = 0.25), (r = 0.11, p = 0.56)]. When we stratified our population by CD4 + T cell number (400–500 cells/ll, 500–600 cells/ll,
600–700 cells/ll, and > 700 cells/ll), we did not find an association between CD4 + T cell number and ADCC antibody
titer for men or women (Fig. 2). Two-way ANOVA measures
between the sexes at two different viral load categories
(0–4,000 copies/ml and > 4,000 copies/ml) also revealed no
correlation of titer with protection and no difference in this
correlation between men and women ( p > 0.5 in all tests).
Since only one man and one woman had no functional ADCC
activity it was not possible to determine whether the presence
of ADCC activity against HIV correlated with the number of
CD4 + T cells or viral load.
ADCC cross-clade reactivity in HIV-1-infected
men and women
Cross-clade ADCC activity was defined as ADCC activity
demonstrated by an individual who is infected with one clade
of HIV-1, against targets coated with HIV-1 gp120 of another
clade. We wanted to determine whether participants of this
study, who were infected in the United States and other
countries where clade B is the predominant clade of HIV,21–23
had any cross-reactivity against a different clade of HIV, clade
A/E, and if this immune function was influenced by the sex of
the donor. We, therefore, evaluated cross-clade reactivity in
all the HIV-1-positive serum samples of the cohorts of this
study (m/f = 32/32) against gp120 MN (clade B) and gp120 CM
(clade A/E)-coated targets. Combined male and female serum
samples from clade B HIV-1-infected individuals (n = 64) had
significantly high ADCC responses against both clades of
gp120 when compared to the seronegative controls (Student’s
t-test, p < 0.0001 for % SR in both clades; p = 0.03 and p = 0.0096
in LU20 for clade B and clade A/E, respectively) (Fig. 3A).
ADCC activity against clade A/E was slightly less than clade

FIG. 2. Distribution of HIV-1 immune markers according
to detected antibody-dependent cell-mediated cytotoxicity
(ADCC) titers in men and women. ADCC antibody titers
were determined from percent specific release (% SR) values
in a standard 51Cr-release ADCC assay using effector cells
from healthy HIV-1-negative donors, gp120 coupled
CEM.NKR targets, and 10-fold serial dilutions of serum as
the source of antibodies. Serum samples from HIV-1 + men
(n = 32) from the Multicenter AIDS Cohort Study (MACS)
and HIV-1 + women (n = 32) from the Women’s Interagency
HIV Study (WIHS), all asymptomatic with no antiretroviral
treatment (ART) were compared. Scatter plots and mean are
depicted. (A) Distribution of CD4 + T cell numbers according
to ADCC antibody titers in men (circles) and women
(squares). (B) Distribution of viral load (VL) according to
ADCC antibody titers in men (circles) and women (squares).

B activity (Student’s t-test, p = 0.01 and p = 0.001, % SR and
LU20, respectively) (Fig. 3A). When comparing groups of men
and women, cross-clade reactivity in HIV-1-seropositive men
was not significantly different from cross-clade reactivity in
HIV-1-seropositive women, although this activity was
somewhat lower in the female cohort (ANOVA, p = 0.057 and
p = 0.5, % SR and LU20, respectively) (Fig. 3B). As expected,
control seronegative sera (m/f = 5/5) did not have ADCC activity against either gp120 clade.
Discussion
Earlier studies came to conflicting conclusions about the
differences between men and women with respect to HIV-1
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FIG. 3. Cross-clade gp120 antibody-dependent cell-mediated cytotoxicity (ADCC) reactivity in men and women. Serum
samples from HIV-1 + men (n = 32) from the Multicenter AIDS Cohort Study (MACS) and from HIV-1 + women (n = 32) from
the Women’s Interagency HIV Study (WIHS), all asymptomatic and under no antiretroviral (ART) treatment, were incubated
at their ADCC optimal dilution for 3.5 h with 51Cr-labeled CEM.NKR target cells bearing either HIV-1-gp120MN (clade B) or
HIV-1-gp120CM (clade A/E) in the presence of effector cells from healthy donors. Serum samples from HIV-1 - healthy
donors, not participants from the MACS or WIHS cohorts (n = 5 males/5 females), were used as controls. (A) Percent specific
release (% SR; box plot) and lytic unit (LU20; mean – SE) values of combined HIV-1 clade B-seropositive samples (n = 64) are
compared to combined HIV-1-seronegative samples (n = 10) against clade B (clear) and clade A/E (gray). (B) ADCC activity
in groups of men and women was evaluated against different clades of recombinant gp120; clades B (clear) and A/E (gray).
Percent SR (box plot) and LU20 (mean – SE) values are depicted and compared to each other and to seronegative controls.
Significance is defined as p < 0.05. ***p = 0.0001.
infection and progression to AIDS.25–28 However, differences
between HIV-1-specific ADCC antibodies in men and women
have not previously been systematically compared. It is important to clarify these findings so that we will know that a
vaccine that stimulates the production of ADCC antibodies
will protect men and women equally. In the past, several
studies have assessed the significance of ADCC antibodies in
host defense against HIV-1-infected cells;14,29–31 however, the
purpose of these studies was to determine whether there are
differences between men and women in HIV-1 gp120-specific
antibody titers responsible for ADCC activity. To accomplish
this, we obtained serum samples from asymptomatic HIV-1infected individuals matched for CD4 + cell number, HIV-1
viral load, age, and ethnicity and evaluated their ADCC activity (Table 1). Our results suggest that in matched populations of asymptomatic HIV-1-positive men and women with
relatively high CD4 + T cell numbers, there were no differences in the concentration or the functional activity of HIV-1
gp120-specific antibodies that mediate ADCC, assessed either
by % SR or LU20 (Fig. 1).
In previous studies we demonstrated that ADCC antibody
titer correlates positively with CD41 T cell number and inversely with HIV-1 viral load.14,32 Those studies included
longitudinal samples spanning from persons with early HIV-1

infection to AIDS. The current study included only asymptomatic individuals with relatively high CD41 T cell numbers
and low viral loads. It is not surprising then, since the range of
CD41 T cell numbers and viral loads was not broad, that we
did not see a correlation between HIV-1 gp120-specific antibody titers and CD41 T cell number or viral load even when
we stratified our population based on CD41 T cell number
or viral load. This study was designed to compare ADCC
activity in HIV-1-infected men and women in a matched
population and was not designed to see correlations between
ADCC and viral load or CD41 T cell number. The fact that
we found no differences indicates that during asymptomatic stages of HIV-1 infection, men and women have similar
levels of HIV-1 gp120-specific ADCC antibodies (Fig. 2). Since
the individuals evaluated in this study were seropositive
when they entered their respective prospective studies, they
may not have been infected for comparable lengths of time
(i.e., MACS or WIHS). Since men and women may progress
to disease at different rates, their immune responses may not
be at the same stage of maturation even though they have
comparable CD4 cell numbers. Possible sex differences in
ADCC antibodies may be present at later stages of HIV-1
infection; it may be beneficial to evaluate differences in ADCC
activity of HIV-1-infected men and women who have lower
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CD41 T cell numbers, have been infected with HIV for comparable lengths of time, have higher viral loads, and have
more progressive clinical disease.
One man and one woman had no functional ADCC activity
even though they had serum antibodies against HIV. The
presence of antibodies directed toward HIV in serum does not
necessarily mean that these antibodies will have functional
ADCC activity, since not all HIV-specific antibodies or even
all neutralizing antibodies have ADCC activity.33 This is not
the first time that we have observed or reported seeing HIVpositive individuals who do not have serum ADCC activity.
In our studies of paired serum and CVL samples in DATRI
009, we observed that a small percentage of HIV-positive
women had ADCC antibodies in their genital fluids but not in
their serum.15
We also evaluated these 64 HIV-1 clade B-infected
asymptomatic individuals for ADCC activity against target
cells bound with either clade B (homologous) or clade A/E
(heterologous) HIV-1 gp120 (Fig. 3A). The studies presented
in Fig. 3 evaluated each sample at the serum dilution that had
the best activity in our initial experiments. Men and women
had comparable ADCC antibody responses to homologous
clade B HIV-1. As we anticipated, clade B HIV-1-infected individuals had notably higher ADCC activity against clade B,
HIV-1 gp120 MN, than they had against clade A/E, HIV-1
gp120 CM; it is noteworthy that the activity was reduced by
only 16%. These results suggest that HIV-1 gp120-specific
antibodies in the serum of infected individuals in this study
had cross-reactive ADCC antibodies at asymptomatic stages
of infection. These data are consistent with a previous report
of cross-clade ADCC activity in HIV-infected individuals34
and extend this observation, showing that sex does not have
an effect on cross-clade reactivity.
To mediate ADCC, the ADCC antibodies must bind to
epitopes of the virus that are expressed on the surface of infected cells and have an Fc region that will bind to the Fc
receptor of ADCC effector cells. Recent studies in primates
demonstrate that ADCC antibodies arise early after infection,35 while neutralizing antibodies, which are generally
clade specific, arise later in HIV-1 disease progression. Macaque studies indicate that ADCC antibodies have a broader
range of activity than neutralizing antibodies.36
Our studies confirm the cross-clade reactivity capabilities
of ADCC antibodies and extend this observation to ADCC
antibodies in humans. Furthermore, our results show evidence that in both men and women, serum antibodies
from clade B HIV-1-infected individuals have cross-reactivity
to clade A/E HIV-1. An HIV-1 vaccine should have broad
cross-clade reactivity; consequently, it is important to understand the relative likelihood of generating cross-clade reactivity with new HIV-1 vaccine candidates and to identify
what contributions they make to a protective immune response. These findings demonstrate that men and women
behave similarly in response to natural infection and suggest
that they would respond to vaccination with similar HIVspecific ADCC activity. If ADCC antibodies to HIV are considered as a target of vaccine development, this should be
confirmed in the context of a vaccination. To our knowledge,
this study is the first to compare ADCC and cross-clade ADCC
reactivity to HIV-1 in men and women and to show that a
vaccine that stimulates the production of protective ADCC
antibodies would likely protect men and women equally.
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